The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)
Open accessAbstract
Since the advent of the non-vitamin K antagonist oral anticoagulant (NOAC) agents, which act as direct thrombin inhibitors or inhibitors of Factor Xa, clinicians are provided with valuable alternatives to vitamin K antagonists (VKAs). At the same time, electrophysiologists frequently perform more invasive procedures, increasingly involving the left chambers of the heart. Thus, they are constantly faced with the dilemma of balancing the risk for thromboembolic events and bleeding complications. These changes in the rapidly evolving field mandate an update of the European Heart Rhythm Association (EHRA) 2008 consensus document on this topic.1 The present document covers the antithrombotic management during different ablation procedures, implantation or exchange of cardiac implantable electronical devices (CIEDs), as well as the management of peri-interventional bleeding complications. The document is not a formal guideline and due to the lack of prospective randomized controlled trials (RCTs) for many of the clinical situations encountered, the recommendations are often ‘expert opinion’. The document strives to be practical for which reason we subdivided it in the three main topics: ablation procedure, CIED implantation or generator change, and issues of peri-interventional bleeding complications on concurrent antiplatelet therapy. For quick reference, every subchapter is followed by a short section on consensus recommendations. Many RCTs are ongoing in this field and it is hoped that this document will help to prompt further well-designed studies. In patients with symptomatic paroxysmal or even persistent atrial fibrillation (AF), catheter ablation is indicated when antiarrhythmic drugs have failed in controlling recurrences or even as a first-line therapy in selected patients.2–4 Patients with AF have an increased risk of thromboembolic events, which varies according to the presence of several risk factors.5,6 Apart from their intrinsic thromboembolic risks, ablation in these patients increases thromboembolic risk due to the introduction and manipulation of one or more catheters and long sheaths into the left atrium, and also due to endocardial lesions produced during ablation. Cerebral imaging studies have shown embolic events post-ablation without clinical overt cognitive deficits.7 The management of anticoagulation during ablation for the prevention of thromboembolic events may, on the other hand, increase the risk of bleeding complications during the procedure (Table 1). Data from the literature on stroke/TIA and tamponade rates during AF ablation RCT, randomized controlled trial; A4, atrial fibrillation ablation versus antiarrhythmic drugs; CACAF, catheter ablation for the cure of atrial fibrillation; MANTRA-PAF, medical antiarrhythmic treatment or radiofrequency ablation in paroxysmal atrial fibrillation; RAAFT, radiofrequency ablation atrial fibrillation trial; STOP AF, sustained treatment of paroxysmal atrial fibrillation; TIA, transient ischemic attack. The antithrombotic strategy in patients undergoing AF ablation includes three different stages: pre-procedural treatment, peri-procedural anticoagulation, and post-procedural strategy. Based on the 2012 Heart Rhythm Society/European Heart Rhythm Association/ European Cardiac Arrhythmia Society (HRS/EHRA/ECAS) consensus document of AF Ablation, the minimum criteria concerning anticoagulation at the time of AF ablation are those that apply to cardioversion of AF.2 All patients undergoing AF ablation who present in AF for the procedure should be anticoagulated for at least 3 weeks prior to AF ablation. If they have not been anticoagulated prior to ablation, a transoesophageal echocardiography (TEE) should be performed. In addition to adhering to these well-established anticoagulation guidelines that apply to cardioversion, the 2012 HRS/EHRA/ECAS consensus document recommends that all patient being anticoagulated during AF ablation with heparin to achieve an activated clotting time (ACT) of at least 300 s. This writing group fully supports these prior minimum recommendations for anticoagulation. Despite the lack of controlled trials, there is a general trend to consider starting antithrombotic treatment before ablation,17 even in patients who present for ablation in sinus rhythm. The higher the patient's stroke risk profile, the lower the threshold is to start anticoagulation prior to ablation. This approach is in keeping with current anticoagulation guidelines that apply to all AF patients. The current guidelines recommend that the initial step is to identify low-risk patients (CHA2DS2-VASc score = 0 for males and 1 for females) who do not need any antithrombotic therapy (Step 1). Subsequent to this step, it is recommended that all patients with a CHA2DS2-VASc score of ≥2 should be anticoagulated, and that anticoagulation should also be considered for males with a CHA2DS2-VASc score of 1 (Step 2).18 For those patients treated with a VKA or a NOAC, the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Cappato, R., Calkins, H., Chen, S.-A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.-H., Klein, G., Natale, A., Packer, D., et al. (2010) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.109.859116 · Cited by 2,852
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
Tang, A. S. L., Wells, G. A., Talajic, M., Arnold, M. O., Sheldon, R., Connolly, S., Hohnloser, S. H., Nichol, G., Birnie, D. H., Sapp, J. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009540 · Cited by 1,859
Self-citationWazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121
Blomstrom-Lundqvist (2003) · doi:10.1161/01.cir.0000091380.04100.84 · Cited by 955
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., Pehrson, S., Englund, A., Hartikainen, J., Mortensen, L. S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113566 · Cited by 720
Calkins, H., Yong, P., Miller, J. M., Olshansky, B., Carlson, M., Saul, J. P., Huang, S. K. S., Liem, L. B., Klein, L. S., Moser, S. A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.262 · Cited by 611
Self-citationMont, L., Bisbal, F., Hernández-Madrid, A., Pérez-Castellano, N., Viñolas, X., Arenal, A., Arribas, F., Fernández-Lozano, I., Bodegas, A., Cobos, A., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht457 · Cited by 394
Clarkesmith, D. E., Pattison, H. M., Lip, G. Y. H., & Lane, D. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074037 · Cited by 209
Self-citation
Cited by
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citationKusumoto, F. M., Schoenfeld, M. H., Wilkoff, B. L., Berul, C. I., Birgersdotter-Green, U. M., Carrillo, R., Cha, Y.-M., Clancy, J., Deharo, J.-C., Ellenbogen, K. A., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.09.001 · Cited by 1,199
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Self-citationHeidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Self-citation
Metadata
- Authors
- Sticherling, C., Marin, F., Birnie, D., Boriani, G., Calkins, H., Dan, G.-A., Gulizia, M., Halvorsen, S., Hindricks, G., Kuck, K.-H., Moya, A., Potpara, T., Roldan, V., Tilz, R., Lip, G. Y. H., ESC Scientific Document Group, Gorenek, B., Indik, J. H., Kirchhof, P., Ma, C.-S., Narasimhan, C., Piccini, J., Sarkozy, A., Shah, D., & Savelieva, I.
- Venue
- EP Europace
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-23
- Volume
- 17
- Issue
- 8
- Pages
- 1197-1214
- ISSN
- 1099-5129 (ISSN-L)
- 1532-2092
- OpenAlex
- W2277499309
- Cited by
- 197
- References
- 13
- FWCI
- 20.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). https://app.cochat.ai/papers/10.1093/europace/euv190
- The paper
- Sticherling, C., Marin, F., Birnie, D., Boriani, G., Calkins, H., Dan, G.-A., Gulizia, M., Halvorsen, S., Hindricks, G., Kuck, K.-H., Moya, A., Potpara, T., Roldan, V., Tilz, R., Lip, G. Y. H., ESC Scientific Document Group, Gorenek, B., Indik, J. H., Kirchhof, P., . . . Savelieva, I. (2015). Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). EP Europace. https://doi.org/10.1093/europace/euv190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.